entertainment -WSS

entertainment

author：leisure time 2025-10-04 03:40:30 - browse：8

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

hotspot

WSS

As AI regulations shape up, health tech startups beg for clarity

Opioid cravings were reduced by anti

New CMS data security rules will hurt Medicare, Medicaid research

Readout LOUD podcast: possible new ALS drug, artificial wombs

How AI helped researchers track recovery from depression

Hospitals are piloting generative AI tools as regulators play catch

entertainment

entertainment

focus

Medicare details structure of new drug price negotiation program

STAT Virtual Event: Putting AI to the Test

Medical records are filled with copy

Weight loss drugs aren’t covered by Obamacare. That may change

Dobbs anniversary: the lost opportunity of abortion as health care

Ukraine seeks to reclaim its role as a hub for clinical trials

Apple is now the first public company to be valued at $3 trillion

Hospitals are piloting generative AI tools as regulators play catch

Virginia high school admissions case could be legal follow

WATCH: Why do our ears pop?

knowledge

Biotech stock slump in 2023: awaiting the turnaround

Hearing on Medicare drug price negotiation gets unusually heated

WATCH: Why do our ears pop?

It's been 20 years since Dolly the sheep. Where's my clone?

Medicare Advantage enrollment hits roughly 33.4 million

Hearing on Medicare drug price negotiation gets unusually heated

hotspot

hotspot

Wikipedia

hotspot